NCT00655928

Brief Summary

The purpose of this study is to determine whether N-acetylcysteine given intravenously 1 day pre-operatively is effective in preventing inflammation in the lungs, as measured by tests on blood, breath and lung specimens, in patients undergoing surgery to remove a portion of lung.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Aug 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2008

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 10, 2008

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2009

Completed
10.2 years until next milestone

Results Posted

Study results publicly available

September 23, 2019

Completed
Last Updated

February 5, 2020

Status Verified

February 1, 2020

Enrollment Period

1.9 years

First QC Date

April 4, 2008

Results QC Date

August 22, 2019

Last Update Submit

February 3, 2020

Conditions

Keywords

Acute lung injuryLung resection

Outcome Measures

Primary Outcomes (1)

  • Post-operative Plasma IL-6

    Plasma IL-6 was measured in duplicate using ELISA.

    Post operative, 24 hours

Study Arms (2)

N-acetylcysteine

EXPERIMENTAL

Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively

Drug: N-acetylcysteine

Placebo

PLACEBO COMPARATOR

Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively

Drug: 0.9% saline

Interventions

N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively

N-acetylcysteine

0.9% saline 1 litre intravenous over 12 hours pre-operatively

Also known as: placebo
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Elective lung resection for cancer

You may not qualify if:

  • Age less than 18 years
  • Women of child-bearing age or potential
  • Known allergy to N-acetylcysteine
  • Oral steroid in the preceding 1 month
  • N-acetylcysteine in the preceding 1 month
  • Unable to receive standardised anaesthetic approach

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Brompton Hospital

London, SW3 6NP, United Kingdom

Location

Related Publications (1)

  • Bastin AJ, Davies N, Lim E, Quinlan GJ, Griffiths MJ. Systemic inflammation and oxidative stress post-lung resection: Effect of pretreatment with N-acetylcysteine. Respirology. 2016 Jan;21(1):180-7. doi: 10.1111/resp.12662. Epub 2015 Oct 27.

MeSH Terms

Conditions

Acute Lung Injury

Interventions

AcetylcysteineSaline Solution

Condition Hierarchy (Ancestors)

Lung InjuryLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

CysteineAmino Acids, SulfurSulfur CompoundsOrganic ChemicalsAmino AcidsAmino Acids, Peptides, and ProteinsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Limitations and Caveats

The investigator did not sample the pulmonary compartment for markers of inflammation or oxidative damage due to reliance on OLV during surgery, may have led to underestimation of pulmonary inflammation and effect of antioxidant supplementation.

Results Point of Contact

Title
Mark J Griffiths
Organization
Imperial College LOndon

Study Officials

  • Mark J Griffiths

    Imperial College London

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2008

First Posted

April 10, 2008

Study Start

August 1, 2007

Primary Completion

July 1, 2009

Study Completion

July 1, 2009

Last Updated

February 5, 2020

Results First Posted

September 23, 2019

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations